Navigating a complex drug development landscape, sponsors must rethink their approach to risk in study design and execution.
Mary Gunn, PhD, MBA
Advertisement
CEO of Emerald Clinical Trials
Articles by Mary Gunn, PhD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Closing the Medical Writing Capacity Gap: Why Training Beats Technology
2
How Much of the Community Participation Gap Is About Infrastructure, Not Willingness?
3
What It Would Take to Make Community Trials Accessible and Scalable
4
Measuring What Matters: Realigning Clinical Endpoints with Patient Reality
5